Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Cabozantinib
Related studies linked through entity extraction aliases.
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
- Status
- COMPLETED
- Phase
- PHASE2
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation
- Status
- UNKNOWN
- Phase
- PHASE2
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- Status
- RECRUITING
- Phase
- PHASE2
Pan Tumor Rollover Study
- Status
- RECRUITING
- Phase
- PHASE2
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
- Status
- UNKNOWN
- Phase
- PHASE2
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Status
- RECRUITING
- Phase
- PHASE1
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Cabozantinib in Advanced Salivary Gland Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- Status
- TERMINATED
- Phase
- PHASE3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
- Status
- COMPLETED
- Phase
- PHASE2